This gene therapy item targets lipoprotein lipase deficiency.

Amsterdam Molecular Therapeutics commences preregistration trial for Glybera Amsterdam Molecular Therapeutics announced today the treatment of the first patient in a preregistration clinical trial with Glybera. This gene therapy item targets lipoprotein lipase deficiency , a debilitating and potentially lethal disease seriously issue . The randomized controlled trial has been made to gather extra data on the effects of Glybera on lipid rate of metabolism and the mechanisms underlying the prevention of pancreatitis episodes.

I am thrilled to see the Amsel Occluder Device enter clinical practice once it receives FDA pre-market clearance. Arnold Miller, MD, Founder and President of Amsel Medical Company commented, We are thrilled to possess filed the first Pre-Advertising Notification ) with FDA for the Amsel Occluder Device. We anticipate significant medical interest because of this innovative technology in the markets where in fact the Amsel Occluder Gadget will be cleared for industrial distribution. This is the first in a series of regulatory filings, while the development is continued by us of several additional Amsel Occluder products. .. Amsel Medical files 510 Pre-Advertising Notification with FDA for Amsel Occluder Device Amsel Medical Corporation today announced that it has successfully completed filing of a Pre-Marketing Notification ) with the US Food and Medication Administration for its Amsel Occluder Device.